Abstract
After the discovery and characterization of the H3R and H4R receptors, they have become widely anticipated as potential therapeutic agents in the treatment of sleep disorders. In preliminary studies, histamine H3 receptor (H3R) antagonists and inverse agonists have demonstrated promise in the treatment of sleep disorders associated with excessive daytime sleepiness. This review article summarizes the current research in this area and characteristics of H3R and H3R antagonists and inverse agonists in development.
Keywords: Histamine, H3 receptor, H3R antagonists, histamine H3 receptor H3R inverse agonists, narcolepsy treatment, excessive daytime sleepiness, antihistamine, sleepiness, narcolepsy, metabotropic, tuberomammillary, diurnal, orexin, preoptic, accumbens, globus pallidus, substantia nigra, presynaptically, norepinephrine, thioperamide
Current Pharmaceutical Design
Title: Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders
Volume: 17 Issue: 15
Author(s): Meredith Broderick and Tony Masri
Affiliation:
Keywords: Histamine, H3 receptor, H3R antagonists, histamine H3 receptor H3R inverse agonists, narcolepsy treatment, excessive daytime sleepiness, antihistamine, sleepiness, narcolepsy, metabotropic, tuberomammillary, diurnal, orexin, preoptic, accumbens, globus pallidus, substantia nigra, presynaptically, norepinephrine, thioperamide
Abstract: After the discovery and characterization of the H3R and H4R receptors, they have become widely anticipated as potential therapeutic agents in the treatment of sleep disorders. In preliminary studies, histamine H3 receptor (H3R) antagonists and inverse agonists have demonstrated promise in the treatment of sleep disorders associated with excessive daytime sleepiness. This review article summarizes the current research in this area and characteristics of H3R and H3R antagonists and inverse agonists in development.
Export Options
About this article
Cite this article as:
Broderick Meredith and Masri Tony, Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197133
DOI https://dx.doi.org/10.2174/138161211796197133 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease
Current Alzheimer Research The Neuronal Cytoskeleton as a Potential Therapeutical Target in Neurodegenerative Diseases and Schizophrenia
Current Drug Targets - CNS & Neurological Disorders Coumarins as Promising Scaffold for the Treatment of Age-related Diseases – An Overview of the Last Five Years
Current Topics in Medicinal Chemistry Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 Kinase and JNK Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Treatments for COPD in the Elderly
Current Pharmaceutical Design Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions
Current Pharmaceutical Design Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Retinal Imaging: A New Tool for Studying Underlying Liability to Cardiovascular Disease in Schizophrenia
Current Psychiatry Reviews Lithium in Psychiatry-The Benefits and Risks Associated with the Lithium Salts Treatment in Affective Disorders
Current Psychopharmacology Pharmacological Management of Psychosis in Parkinson Disease: A Review
Current Drug Therapy Oxidative Stress in Post-Acute Ischemic Stroke Patients after Intensive Neurorehabilitation
Current Neurovascular Research Change in INSR, APBA2 and IDE Gene Expressions in Brains of Alzheimer's Disease Patients
Current Alzheimer Research Inhibition of Neurofibrillary Degeneration: A Promising Approach to Alzheimers Disease and Other Tauopathies
Current Drug Targets Clinical Trajectories and Biological Features of Primary Progressive Aphasia (PPA)
Current Alzheimer Research Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology Commentary 2 (The Contribution of Glial Cells and Water Channel Aquaporin-4 in the Neuropathology of Cardiac Arrest is Still Ignored)
CNS & Neurological Disorders - Drug Targets Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies
Current Pharmaceutical Design